Replies to post #46886 on Premier Biomedical Inc (BIEI)

[work-n-hard]

It is what it is. Of course, this doesn't mean that with a big distribution agreement, they can't get the PPS up in a couple of months. But, until then, I am looking for it to stay somewhere in the .006 - .01 range.
That is my honest opinion!

Page 21 of the new S-1:

All information with respect to common stock ownership of the Selling Shareholders has been furnished by or on behalf of the Selling Shareholders and is as of August 17, 2017. Because the Selling Shareholders may sell some or all of the shares included in this Prospectus, and because there are currently no agreements, arrangements or understandings with respect to the sale of any of the shares, no estimate can be given as to the number of shares available for resale hereby that will be held by the Selling Shareholders in the future. In addition, the Selling Shareholders may have sold, transferred or otherwise disposed of, or may sell, transfer or otherwise dispose of, at any time and from time to time, the common stock it holds in transactions exempt from the registration requirements of the Securities Act after the date on which it provided the information set forth on the table below. We have, therefore, assumed for the purposes of the following table, that the Selling Shareholders will sell all of the shares owned beneficially by it listed in the table below that are covered by this Prospectus. Shares in the table below refer to shares of our outstanding common stock.

Page 20 of the new S-1

After giving effect to the issuance of convertible notes and sale of 105,000,000 shares of common stock by the Selling Shareholders, and at an assumed average sale price of $0.0067 per share (the closing price of our common stock as of August 22, 2017 ($0.0112) at a 40% discount), our pro forma as adjusted net tangible book value as of December 31, 2016 would have been approximately $(60,704), or ($0.0002) per share of Common Stock. This represents an immediate increase in pro forma as adjusted net tangible book value of $0.0020 per share to our existing shareholders and an immediate dilution of $(0.0069) per share to our new shareholders.